Empowering worldwide biopharmaceutical innovators and nutraceutical brands with validated botanical validation, molecular screening, and clinical-grade pharmacological evidence.
Empirical pharmacology requires indisputable rigor. Our 14+ years of data synthesis bridge Traditional Chinese Medicine (TCM) empirical wisdom with Western bio-molecular assays.
Multi-target synergy verification. We deploy enzyme-inhibition kinetics, receptor-binding affinities, and transcriptomics profiling to map molecular pathways (e.g., NF-κB downregulation, AMPK phosphorylation) for intricate natural compounds.
Our translation pipeline has registered 56 in-hospital preparations with regulatory authorities, proving compliance with stringent clinical efficacy benchmarks and real-world batch stability protocols.
Entrusted research and manufacturing conducted behind isolated secure infrastructure. Client formulas, chromatographic data sets, and downstream processing specifications remain strictly confidential under NDA covenants.
Navigating escalating regulatory scrutiny from the US FDA, EMA, and NMPA requires transitioning from crude extract assertions to verified pharmacological mechanisms.
Historically, botanical nutraceuticals relied heavily on observational history. Western markets now demand quantitative active markers and reproducible cellular mechanisms. Without HPLC fingerprinting and receptor binding validation, overseas market approvals encounter severe bottlenecks.
Soil geology, microclimates, and harvest timings cause bioactive potency shifts up to 340% within identical botanical species. Global suppliers without raw origin evaluation face regulatory rejections, diminished bio-efficacy, and severe liability under commercial recalls.
Conducting comprehensive in vitro, pharmacokinetic (PK/PD), and in vivo animal screening in North American or European labs often requires 3x to 5x higher financial expenditure with protracted timelines, severely slowing pipeline viability for mid-sized pharmaceutical enterprises.
Integrating primary botanical cultivation clusters with high-throughput pilot-scale processing and ISO/cGMP certified manufacturing facilities.
Direct integration with native Chinese botanical cultivation habitats. We map altitude, UV exposure, and seasonal phenology across thousands of hectares, extracting maximum compound density for alkaloids, flavonoids, and active polysaccharides directly at source.
Eliminating intermediate CDMO handoff friction. Our proprietary pilot plants transition research-validated processes directly into industrial multi-ton reactors, macroporous adsorption resin columns, and vacuum spray dryers without loss of pharmacological activity.
Hunan’s centralized logistics infrastructure, backed by temperature-controlled multi-modal air and sea corridors, guarantees uninterrupted shipment of active botanical ingredients (APIs), standardized extracts, and packaged finished dosage units globally.
Pharmacological evaluations customized to address distinct regional market demands, therapeutic criteria, and end-consumer delivery forms.
Substantiating structure-function claims for North American and European retail sectors. We conduct blinded human pilot trials, antioxidant ORAC assays, and inflammatory cytokine suppression assays for high-demand wellness applications.
Supporting IND dossiers with systematic GLP animal studies (rodent and canine models), pharmacokinetic profiles, bio-distribution pathways, acute LD50 determination, and 90-day sub-chronic toxicity reports acceptable to regulatory authorities.
Validating topical permeation and cellular repair efficacy. Testing includes tyrosinase inhibition for skin brightening, elastase suppression for anti-aging, and skin irritation patch testing conforming to international cosmetic regulations.
Pioneering the next generational leap in botanical pharmacology through automated molecular docking, multi-omics, and advanced microfluidic human-tissue testing.
Utilizing neural network models to computationally predict ligand-protein binding energies across millions of plant metabolome configurations, cutting initial screening durations from months to hours.
Integrating 3D microfluidic gut-liver barrier chips to replicate human systemic metabolization in real-time, providing unprecedented precision in bio-accessibility without premature animal sacrifice.
Establishing continuous blockchain and AI-indexed chemometric profiles that link raw harvest environmental parameters directly to finished clinical bio-equivalence curves.
Bridging international pharmacopeial thresholds. Comprehensive analytical dossiers configured for direct submission across worldwide authorities.
Delivering toxicological validation packages, 14-day acute toxicity, Ames bacterial reverse mutation tests, in vitro micronucleus assays, and batch reproducibility datasets required for US FDA NDI notifications.
Compliance testing tailored to European Pharmacopoeia (Ph. Eur.) guidelines, including heavy metal quantification (ICP-MS), pesticide residue multiclass screening (LC-MS/MS), and aflatoxin limits.
Seamless operational interface. Our team provides full English-language validation packages, raw chromatographic audit trails, and on-site or virtual quality audit support for overseas quality assurance teams.
Collaborative analytical research, hospital formulation standardizations, and contract manufacturing delivered for industry leaders.
Tongrentang Group
China Resources Sanjiu
Sunflower Pharma
Livzon Pharma
Dihon Pharma
Golden Throat Group
Yangtzi River Pharma
Beihai Gofar Biological
Humanwell Healthcare
SCIMYTH Pharma
Shandong Hanfang
Luoxin Pharma
Zhongsheng Pharma
Apeloa Pharma
Heng Chang Pharma
Kangmei Pharma
Shuguang Hospital
Second Xiangya Hospital
Key considerations for R&D executives, formulation scientists, and CDMO contract procurement teams.
Select standard pharmacological packages or commission specialized custom extraction and bioassay protocols directly through our technical team.
